Registered number." 02165552
Charity number: 519357
NORTH WEST CANCER RESEARCH (INCORPORATING CLAThERBRIDGE
CANCER RESEARCH "CCR")
TRUSTEES, REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
CONTENTS
Page
Reference and administratlve details of the charlty, its Trustees and advlsers
Chair's Statement
Trustees, Report
7-19
Independent Auditorfs Report
20-24
Consolldated Statement of Flnanclal Actlvltles
25
Consolidated Balance Sheet
26
Charlty Balance Sheet
27
Consolldated Cash Flow Statement
28
Notes to the Flnanclal Statements
29-52

NORTH WEST CANCER RESEARCH (INCORPORATING CLAThERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND
ADVISERS FOR THE YEAR ENDED 30 SEPTEMBER 2024
Trustees and officers of the Board
Miss C M Jones BA, ACG
Chairman and Chair of the Nominations & Remuneration Committee
Mr S Anantharaman
Mrs H Atherton
Dr M Carter CPsychol AFBPSS Vice Chair
Mrs J Clague
Appointed 26 April 2023 and Honorary Treasurer from that date
Mr M Haig
Resigned 20 May 2024
Ms F Hewison
Dr S Kothari
Mr P Moonan
Mrmore
Dr P Robertshaw PhD, Dip DM
MrA Stalker
Mrj Willis
Chair of the Marketing and Fundraising Commlttee
Resigned 31 December 2024
Chair of the Investment Committee
Patrons
The Most Reverend Malcolm Mcmahon
The Right Reverend Mark Tanner
The Right Reverend John Perumbalath
The Right Reverend Gregory Cameron
The Right Reverend Peter Eagles
The Right Reverend Beverley Mason
Mark Blundell
Prof Tim Jones
Prof Mark Power
Prof Calum Semple
The Most Honourable David Cholmondeley
Lord Mostyn
Dame Lorna Muirhead
Henry Bowring
The Archbishop of Liverpool
The Lord Bishop of Chester
The Bishop of Liverpool
The Bishop of St A5aph
The Bishop of Sodor and Man
The Bishop of Warrington
Lord Lieutenant of Merseyside
The Vice Chancellor, The University of Liverpool
The Vice Chancellor, Liverpool John Moores University
The President of the Liverpool Medical Institution
The Marquess of Cholmondeley

NORTH WEST CANCER RESEARCH (INCORPORATING CLAThERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND
ADVISERS FOR THE YEAR ENDED 30 SEPTEMBER 2024 (continued)
Registered office
North West Cancer Research
Room G5
Liverpool Science Park
131 Mount Pleasant
Liverpool
L3 5TG
Bankers
Sollcitors
Brabners LLP
Horton House
Exchange Flags
Liverpool, L3 9QJ
Natwest
247 High Street
Bangor
Gwynedd,LL57 IRW
Investment Managers
Rathbones Ilncorporating Investec Wealth and Investment Ltd.)
Port of Liverpool Building
Mann Island
Liverpool, L3 INW
Audltors
Crowe U.K. LLP
3rd Floor
St George's House
56 Peter Street
Manchester, M2 3NQ
Senlor Management Team
Alastair Richards
Ruth Turley
Cara Newton
Alan Lancelott-Redfern
Carol Kirkham
Dr Alison Moore
Chief Executive Officer land Company Secretary)
Head of Finance and Administration
Director of Brand and Income
Head of Retail
Head of Fundraising
Head of Health, Research & Impact

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
CHAIR'S STATEMENT
FOR THE YEAR ENDED 30 SEPTEMBER 2024
The foreword to the Trustees, Report and Financial Statements often focuses purely on financial and
governance matters, but it is useful from time to time to remind readers of why North West Cancer
Research exists and what we seek to do.
Cancer is a huge health issue across the UK, Europe and beyond, but here in the North West we have a
particular problem: the number of cancer cases is higher than you would expect for our population size
and cancers are often diagnosed later, with the result that the treatment pathway is more complex and
outcomes are often poorer.
North West Cancer Research is focussed on our region's cancer needs: our aim is to tackle the excessive
number of cancer cases in our region; to improve diagnosis and treatment. and ultimately to reduce
mortality from cancer, We do this by funding research- research into understanding the causes of cancer
and improving the care of those suffering from cancer, and research that ultimately seeks to find cures for
the many different types of cancer. In addition, we have an important message to communicate to the
people of the region: how they can reduce their own cancer risk, recognise the symptoms of cancer early
and get the most appropriate treatment.
Our task is substantial and we do not underestimate the challenges ahead. As we continue to make
progress, it is important that we maximise the resources we have available and use them well. Wherever
possible, we will work In partnership with others in order share the load and to further our purpose and
priorities.
The financial year ending 30 September 2024 has continued to be a time of change and challenge. At the
start of the year, cost inflation was a significant factor in the economy and, combined with increasing
interest rates, this means that many supporters in our region were and are seeing their disposable income
decrease. We are extremely fortunate that this does not seem to have impacted significantly upon our
income in-year, but we are very conscious of the challenges ahead of us.
Our financial results reflect a positive picture for the year: even though our overall income decreased, our
income from fundraising and donations increased, up from £1.67k in 2022/23 to almost £1.77m. This
included income from the Medical Research Council to support early career researchers, along with a
number of sizeable trust grants to support both our research and outreach work.
Income from legacies in the year was smaller than for 2022/23, when we were fortunate to receive a
number of substantial legacy gifts which added significantly to our income, but legacy gifts still
contributed almost £644k to the resources we had available, and for this we are very grateful. The gifts
left as legacies are often the largest single gift an individual can Eive and we recognise that, without

NORTH WEST CANCER RESEARCH {INCORPORATING CLArrERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
CHAIR'S STATEMENT
FOR THE YEAR ENDED 30 SEPTEMBER 2024 {continued)
these, much important research would not be funded. The charity also received income from investment
returns which contributed £316kto our overall funds (compared with £280k in 2022/23}, while investment
growth added a very substantial £l.Im to the funds available.
We are delighted that, during this year, we have been able to continue funding excellent new research
projects and that competition for funding remains intense. During the twelve months covered by this
report, we have funded projects in translational research, applied research and regional inequalities. We
were excited to provide continuation funding for our work on triple-negative breast cancer research at
Lancaster University and we are hopeful that the new drug developed - which appears to work so well in
the lab to kill cancer cells with limited side effects- can be successfully moved towards patient application.
Other projects funded included new network of bowel cancer researchers, and a contribution towards a
national audit of head and neck cancer patient outcomes.
In writing this report, I want to take the opportunityto thank my Board of Trustees, who continue to work
so hard on behalf of NWCR, supporting and guiding the charity in taking forward its work and providing
excellent advice to me and to the charity's management team.
I would also like to express my gratitude to the CEO, Alastair Richards, to the whole staff team and to all
those who have been involved with NWCR during 2023124. Like many other charities, we are reliant upon
our donors and those who kindly leave us gifts through legacies. NWCR also has the benefit of having in
place local branches which give us such dedicated and enthusiastic support and which continue to develop
their presence In towns across our region. We have also received excellent backing from our Patrons,
Ambassadors and many volunteers and we recognise the growing support which we receive from
corporate funders.
Looking forward, NWCR, like many charitie5, faces challenges and uncertainties. l and my fellow Trustees
believe, however, that during 2023/24 we have continued to advance the charity's objectives in order to
address cancer more effectively in our region. We believe that we are making progress with this challenge
and we are confident that this will continue in the coming years.
Name Catherine Jones BA ACG
Chair
30 January 2025

NORTH WEST CANCER RESEARCH (INCORPORATING CLAThERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
TRUSTEES, REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2024
The Trustee5 {who are also directors of the Charity for the purposes of the Companies Act) present their
Annual Report, together with the audited Financial Statements of North West Cancer Research
(incorporating Clatterbridge Cancer Research "CCR") (the Company) for the year ended 30 September
2024. The Trustees confirm that the Financial Statements comply with the Charities Act 2011, the
Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by
Charities: Statement of Recommended Practice applicable to charities preparing their accounts in
accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 1021
(effective l January 2019}.
Since the Company qualifies as small under section 383, the Strategic Report required of medium and large
companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is
not required.
STRUCTURE, GOVERNANCE AND MANAGEMENT
The Company Is registered as a charitable company limited by guarantee and was set up by a
Memorandum of Association on 24 September 1998 and revised on l October 2009, 4 October 2012, 22
March 2018 and 29 April 2021. The Company's registered charity number is 519357.
The Board of Trustees {"the Board") is responsible for the overall governance of the Charity. The Trustees
and members of the Board who have served during the period are set out on page 3.
Trustees are normally co-opted onto the Board and their appointment confirmed at the following Annual
General Meeting. Appointment is normally for a period of three years. although this can be renewed
through re-election by the membersto create a maximum term in office of 9 years. Trustees are appointed
to the Board through two routes, with the oversight of any appointment being undertaken by the
Nominations and Remuneration Committee {see below). The majority of appointments are made through
identifying a skills gap amongst the current Trustees and advertising any vacancy. However, the Board
does recognise that there are individuals with exceptional skills or connections which it may be useful to
have on the Board and so the option remains to directly approach potential Trustees.
New Trustees are normally provided with an introduction into the nature and running of the Charity,
including seeing funded researchers in action, meeting the staff team and volunteer fundraising branches.
They are also provided with a raft of information about the Charity, in the form of a Trustees Handbook,
in order to enable them to understand the organisation's history, policies and current position.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
TRUSTEES, REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2024 {continued)
STRUCTURE, GOVERNANCE AND MANAGEMENT (continued)
Board meetings take place fourtimes peryearwith an additional day being taken when needed to consider
strategy or other material questions for the organisation.
It is the responsibility of the Board to develop organisational strategies in partnership with the
management team and to review operational performance, to set budgets and to approve operational
plans. The Board delegates the exercise of certain powers as set out below. This is controlled through
regular reporting back to the Board so that Trustees can oversee all decisions made under delegated
powers. The Committees and individuals to which the delegation takes place are shown below:
a. Officers of the Board
There are three officers of the Board to whom responsibilities are delegated. These are the Chalr,
the Vice-chair and the Honorary Treasurer. The Chair acts as the main link from the Trustees to
the Chief Executive Officer and is also a key external representative for the Charity. The Chair also
ensures that decisions are lawful, constitutional and within the remit of the Charity. In their
absence, the role is covered by the Vice-chair. The Honorary Treasurer oversees the financlal
affairs of the organisation and supports the Board on financial reporting and compliance.
b. Marketlng and Fundralsing Commlttee
Working closely with the Director of Brand and Income and the Fundraising Team, the Committee
provides advice and assurance to the Board. It also has key responsibilities in approving strategic
and annual plans for marketing, communications and fundraising activities and for assessing the
effectiveness of these.
Investment Commlttee
The Committee seeks to provide advice and assurance to the Board in overseeing the Charity's
investments and the performance of those. This includes recommending to the Board the
approval of the Charity's Investment Policy along with the appointment or re-appointment of
investment and other related professional advisers.
d. Nominations and Remuneration Committee
The Nominations and Remuneration Committee oversees and recommends to the Board key
appointments for the Charity as well as remuneration for the senior staff team. This includes
members of the Board of Trustees, Officers of the Board and the appointment of the Chief
Executive Officer. The Committee also oversees the membership of the Charity and, in addition,
the appointment of Honorary Members and Patrons.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
TRUSTEES, REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2024 (continued)
STRUCTURE, GOVERNANCE AND MANAGEMENT (continued)
Chlef Executive Officer
The Chief Executive Officer is responsible for day-to-day management of the Charity's affairs and
for implementing policies agreed by the Board. The Chief Executive is assisted by a team of
senior managers and other staff.
In addition to the Committees and individuals above to whom responsibilities are directly delegated,
note should also be made of the Groups which advise the Board on the quality of research applications
received and what should be funded. These are:
Cancer Discovery Advisory Group
The Cancer Discovery Advisory Group undertakes the scientific assessment of applications for
early stage research funding looking at cell structures, DNA and proteomics.
Translatlonal Research Advlsory Group
The Translational Research Advisory Group considers projects which seek to develop
theoretical knowledge and start to identify how It can be applied to patients and technlques
which will benefit the population.
Applied Research Advisory Group
The Applied Research Advisory Group reviews funding applications for projects which seek to
improve the effectiveness and experience of current treatments being used in our area.
Inequalltles Advisory Group
The Inequalities Advisory Group reviews studies on cancer inequalities including projects
which study differences in how different parts of the diverse community in our area
experience cancer, and receive and respond to information, advice and treatment.
PhD Funding Group
This panel oversees the awarding of funding for a number of PhDs. The panel comprises a
broad range of researchers including a number of current NWCR PhD students. PhDs are
awarded in a range of disciplines from cancer discovery to applied work.
Not every group will meet and review projects in every year and groups are convened and updated as
necessary in order to meet funding plans. The recommendations from each group are considered by the
Board of Trustees along with any recommendations for process improvements . In addition to the groups
above the Charity also forms advisory panels to consider individual projects where these fall outside the
remit of one of the groups above or where projects are being funded in partnership with another charity.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
{A company limited by guarantee)
TRUSTEES. REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2024 (continued
STRUCTURE, GOVERNANCE AND MANAGEMENT (continued)
PUBLIC BENEFIT
The Trustees have given due consideration to the Charity Commission's guidance on public benefit as is
required under the Charities Act 2011. The Report below provides detailed information on the activities
underta ken by the Charity. All of the Charity's activities are directly in the public benefit and there are no
financial benefits from the award of research funding.
The outcomes of the research are for the public benefit. The benefits are primarily for those who suffer
from the types of cancer covered by our research. Society generally benefits as improved treatment
reduces the numbers of, and stress from anxiety from, early deaths from cancer.
OBJECTIVES, ACTIVITIES AND ACHIEVEMENTS
a. Objectlves
North West Cancer Research is dedicated to putting our region's cancer needs first, funding pioneering
research to tackle the cause, improve the care and find the cure for cancer. We focus on the types of
cancer that affect people living across North West England and North Wales the most.
The objects of the Charity las adopted in April 2021) read as follows:
to promote and carry out research into cancer, its diagnosis and its treatment and to
disseminate the results of such research to the public. and
to educate the public in respect of all matters relating to cancer and its diagnosis, treatments
and effects and impact upon a person, so that the public may better understand cancer, its
impact, its causes and how best to avoid such illness or conditions, including advice about
lifestyle and other contributory factors (the "Objects").
Our strategy has a number of strands including a drive to understand why cancer rates and mortality are
high in our region, creating a broad research pipeline and finally providing communities with information
on the signs, symptoms and treatments for cancer as well as advice on making healthy life-style decisions.
In each financial year the Trustees allocate funds to the activities in line with a five-year plan and these are
then used in order to fund research projects, outreach work, campaigns and other activities. The balance
of funding changes each year depending on the resources available and the agreed priorities.
io

NORTH WEST CANCER RESEARCH (INCORPORATING CLAThERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee}
TRUSTEES, REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2024 (continued)
ACTIVITIES AND ACHIEVEMENTS {continued)
b. Activities and achievements
In the period the Charity has furthered its objectives predominantly through funding research carried out
in Higher Education Institutions and NHS Trusts within the area. In addition we have carried out outreach
and education work and run a number of awareness campaigns. At the present time funded research
programmes are underway at eight institutions across the region including the University of Liverpool,
University of Manchester, Bangor University, Edge Hill University and Lancaster University as well as at
Blackpool Teaching Hospitals NHS Trust. Current funding programmes include:
Funding for research projects which focus on the cause, care or cure for cancer, This might be in
fundamental science, cancer cell biology, translational medicine, drug utilisation, medical practice,
the improvement of treatments or the understanding of inequalities;
Funding for key posts within academic institutions which will build the capacity of research, along
with funding PhD students.
Funding for the incubation of new projects in order to aid the development of early stage
hypotheses;
Currently, there are around 60 active funding streams supporting projects, students, lecturers, fellows and
the development of new research. During the year, 1412022/23: eighteen) research project grants were
awarded at a total cost of £2.49 million (2022123: £2.Omillion). The largest single commitment at this time
is for £500,000 for a multi-year programme grant which creates an interface between the Liverpool Head
and Neck Centre and the academic researchers at the University of Liverpool, accelerating and improving
research. The Charity is also continuing to grow its outreach work across the region and is increasingly
reaching into employers, schools and other community groups in order to provide information about the
risks and symptoms of cancer.
The Charity is a member of the Association of Medical Research Charities and a not for profit partner of
the National Institute for Health and Care Research and this ensures that it complies with strict policies on
peer review for research project funding. Any application received will be subject to scrutiny by the
appropriate group (see above) to ensure that it is research of the highest available standard and that award
is made in an impartial manner.
Funding for research 15 generated through active fundraising, legacy receipts and investment returns. The
Charity benefits from a network of branches or committees of volunteers who organise a wide variety of
fundraising activities to generate income for us. Branches are spread across Cumbria and Lancashire to
the north, Merseyside and Cheshire and also North and Mid Wales.
11

NORTH WEST CANCER RESEARCH (INCORPORATING CLArtERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
TRUSTEES, REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2024 (continued)
ACTIVITIES AND ACHIEVEMENTS (continued)
The Charity is focussed upon growing and diversifying its fundraised income and annually reviews the team
along with the methods used to generate funds. An essential element of this is to draw income from a
wider range of sources including corporates, community Eroups, trusts and individuals while keeping costs
down. As part of its efforts to grow brand awareness and to diversify income, the Charity opened its first
charity shop in February 2024 with a second following in October 2024. Both shops sell donated goods and
are proving to be successful in generating new funds for the Charity. The shops are operated through a
subsidiary company- North West Cancer Research Trading Ltd which ha5 Its own Board of Directors. The
Charity also continues to add to its portfolio of events, engaging the public in generating funds for it.
During the year total income from all sources of fundraising increased to £1,768k {2022:23 £1,673k)
RISK MANAGEMENT
The Trustees have assessed the major risks to which the Charity is exposed, in particular those related to
the operations and finances of the Charity and are satisfied that systems and procedures are in place to
mitigate our exposure to the major risks. The risks to which the organisation is exposed are considered by
the Board at each meeting, with a more in-depth review taking place twice a year. The risk profile will
change over time as the organisation strengthens its controls and considers strategies to mitigate risks.
The risks below are the ones of which the Board is particularly mindful:
Investment risks The organisation holds its reserves in investments which can be subject to
fluctuations in value. The Charity is an investor for the long-term and, as such, it has benefited
significantly from the increase in value of its holdings. However, it is aware of the need to
maintain a balanced portfolio of risks and to spread the profile of its investments in order to
protect itself from short-term fluctuations in the market,"
Reputational risks The Charity sector has seen its reputation significantly impacted in recent
years as a number of scandals have taken place. North West Cancer Research is very aware of
the need to uphold the highest levels of governance and to consider carefully its actions when
fundraising and promoting the organisation. and
Staffing risks- The Charity depends on a dedicated team of staff who are often responsible for
covering multiple roles within their job. Recruiting and retaining quality staff is critica I for any
business - particularly one which depends on fundraising for its income. The Charity annually
reviews the impact of increases in the cost of living and reviews pay and conditions accordingly.
12

NORTH WEST CANCER RESEARCH (INCORPORATING CLAThERBRIDGE CANCER
RESEARCH "CCR")
{A company limited by guarantee)
TRUSTEES, REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 20241continued)
RISK MANAGEMENT (continued)
Like many charities, NWCR is aware of the potential medium- and long-term impacts which may result
from the UK leaving membership of the European Union. Many talented researchers from across Europe
and beyond currently work in academic institutions where the Charity funds work and at this point it is
unclear as to whatthe potential impacts of this change are. The Trustees continue to monitorthis situation
in order to understand the results which may occur.
ACHIEVEMENTS AND PERFORMANCE
a. Golng concern
In recent years, increases in the cost of living pressures have had a significant impact on many parts of the
economy and on many charities. This has caused prices to rise, resulting in the squeezing of the disposable
income of individuals, as well as reducing the capacity to give of many companies. Volatility in investment
markets remains a concern and indeed has impacted the ChariVs balance sheet during the year. However,
after making appropriate enquiries, the Trustees have a reasonable expectation that the Charity has
adequate resources to continue in operational existence for the foreseeable future and there are no
material uncertainties, For this reason, they continue to adopt the going concern basis in preparing the
Financial Statements. All current commitments made to fund research work and posts have been provided
for within the Balance Sheet. Further details regarding the adoption of the going concern basis can be
found in the Accounting Policies within the Financial Statements.
b. Financial review of the year
During the year the headline income of the Charity was £2.84m (2022/23: £2.6ml.
The Charity has traditionally drawn its income from three sources- legacies, fundraising and investment
returns and each of these needs to be considered separately when reviewing performance.
In 2023/24, legacy income fell from the high levels seen in the previous three years, to £0.64m {2022123..
£0.95ml. Legacy income is always unpredictable and the Charity remains deeply grateful for those
supporters who leave us gifts in their will.
Income from fundraising activities and donations, including gifts in kind, increased during the year by £95K,
to £1,768K {2022/23: £1,683k) as the Charity grew its fundraising base but also received income from the
Medical Research Council of £829k. A real area of progress during the year was in income received from
grant making trusts and foundations which increased, with larger grants for funding research and also for
outreach activities. The Charity is grateful to all of its supporters who provide gifts large and small.
13

NORTH WEST CANCER RESEARCH (INCORPORATING CLAThERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
TRUSTEES, REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2024 (continued)
Financial review of the year (continued)
Income from investments increased slightly during the year, to £316k (2022/23 £280k}, thanks largely to
interest earned on sizeable cash balances. Dividend income was on a par with that earned in recent years.
The investment policy and objectives for the North West Cancer Research portfolio is explained below,
under Key Policies. No objectives have been set for the portfolio held in the name of the Cancer Research
and Polio Fund, as it is expected to be drawn on over the next couple of years.
During the year the Charity was delighted to complete 3 number of new grant funding rounds, in a broad
variety of area5. During the year we funded two grants in partnership with The Eve Appeal focussed on
gvnaecological cancers. We were grateful for the opportunity to work together with The Eve Appeal in this
and for their expertise. In addition, we also funded research rounds of our own- for translational science
applied research and inequalities.
The Charity has also grown its investment in education and awareness work and during the financial year
we ran a number of campaigns in areas such as Sun safety, cervical screening awareness, bowel cancer and
others. We also grew and developed our labcoat learning work with outreach into schools and other
community groups to provide education on simple areas of health and wellbeing including healthy diet
and knowing your body.
At the end of the financial year, reserves had fallen from £5.2m to £5.Om, after taking into account a
significant increase in investment values of £l.Im. Our reserves are invested in order to maximise the
returns available and the funds which can be used to further our charitable object5. The significant legacy
receipts accounted for in 2021/22 means that, during the latest financial year, the charity has held large
cash balances which were put into shorter-term deposits to match our known spending patterns while still
generating income.
c. Fundraising
The Charity is registered with the Fundraising Regulator and with the Fundraising Preference Service. It
employs a fundraising team which is overseen by an experienced fundraising manager who ensures that
high standards are maintained at all times. During the year the Charity has started to make use of
commercial fundraisers in order to promote lottery sales and to generate income. It does not exchange
data with other parties and has not purchased supporter mailinE lists.
14

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
TRUSTEES, REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2024 (continued)
Fundraising (continued)
During the year there were two complaint5 (2022/23: one) around fundraising activity. In addition there
were a number of complaints around the use of gender neutral lanEuage in a campaign which we ran
and which triggered a response from a number of people- most of whom were not in the area covered
by the Charity. We always respond to the concerns raised by our donors and believe that these are an
important opportunity for us to learn where we haven't got things right.
NWCR maintains records of all supporters, donors and gifts received and ensures that these records are
regularly reviewed and monitored to check that contact with donors is done in an appropriate manner and
in line with any preference which they have stated to us. Mailings to donors are limited in number and
the Charity does not carry out active telephone fundraising campaigns. The Charity does not knowingly
contact vulnerable individuals or those who have opted out of mailing contact.
d. Reportlng and monltoring performance
The Board of Trustees sets an annual budget against which performance is monitored on a monthly basis.
Management of the budget is delegated (a5 noted above) but Trustees monitor performance against it. A
set of performance indicators is now being developed in order to assist the Board in understanding
management performance and to help in quantifying the impact of our research.
KEY POLICIES
The Board has a number of policies which are key in the operation of the Charity. These are:
a. Investment pollcy and performance
Except for the restrictions imposed by the ethical policy, the Charity places no further restrictions on the
amount or type of investments made by the Charity and adheres to all relevant legislation. During the
year the Charitvs investments were overseen by Rathbones (Incorporating Investec Wealth and
Investment) Ltd., who managed the portfolio on a discretionary basis, within agreed limits, monitored
against an appropriate index, and reviewed on a regular basis by the Trustees. The main objective is to
provide a balance between capital growth and income in order to meet the Charity's future commitments
which, by their very nature, generally run for periods of 3 to 5 years ahead. The Charity's Investment
Strategy targeted an income from the Investment Managers during the year of £241k, which was
comfortably exceeded.
15

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
{A company limited by guarantee)
TRUSTEES. REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2024 (continued)
Investment policy and performance (continued)
The Company has barred investment in tobacco businesses and will not make any new investments in
companies which make a significant proportion of their profits from alcohol and sugar-related products.
Ethical constraints are reviewed regularly by both the Investment Committee and the Board of Trustees,
No social investment is currently undertaken.
b. Reserves policy
The Reserves Policy was reviewed by the Board of Trustees in September 2024 to ensure that it remains
appropriate for the Charity.
North West Cancer Research recognises research grants as they are made, and hence at the end of
financial year 2023/24 it had provided for research costs which will be paid in future years of £6.55m
(2022123: £5.8ml which had been approved but not yet utilised (See Note 41. Having reviewed the other
commitments and contingencies which exist, the Trustees consider that it Is appropriate to set aside
reserves equivalent to 6 months operating costs in order to enable an orderly wind-up of the organisation,
plus a further £2m to fund research work to ensure that projects can be brought to a successful conclusion
in the event of a significant reduction in income and reserves. At the present time, the reserves required
by this policy would be approximately £2.59m against free reserves at the year-end of £5.Om. The Charity
does not designate funds for specific purposes and restricted funds are minimal. The reserves are held in
cash and investments and are not held in fixed assets.
At the present time the organisation has funds above its current reserves target and it will continue to
utllise this to fund research at a rate quicker than revenue would normally allow.
PLANS FOR THE FUTURE
Key targets for 2024/25 include".
To continue to grow and diversify our fundraising income to include a broad range of different
sources. In particular the Charity is keen to grow its lottery and corporate income
To improve how we document and understand the impact of our research work. To this end the
Charity is adopting the ResearchFish package which records the outcomes from funded research
and through which we will collect data for the first time in 2025
16

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
IA company limited by guarantee)
TRUSTEES, REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2024 (continued)
PLANS FOR THE FUTURE (continued)
To continue to grow our number of charity shops operated through our subsidiary, North West
Cancer Research Trading Limited. At the balance sheet date one shop was open and one close to
being open- but by September 2025 we hope to have five shops in operation
To continue to grow our outreach and education work in order to tell more people in the region
about the signs and symptoms of different cancer types.
To enrich our events programme through operating the Liverpool-Chester-Liverpool cycle ride for
the f irst time.
17

NORTH WEST CANCER RESEARCH (INCORPORATING CLAThERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
TRUSTEES, REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2024 (continued)
TRUSTEES, RESPONSIBILITIES STATEMENT
The Trustees (who are also directors of North West Cancer Research {incorporatinE Clatterbridge Cancer
Research "CCR"}I for the purposes of company law are responsible for preparing the Trustees, Report and
the Financial Statements in accordance with applicable law and United Kingdom Accounting Standards
(United Kingdom Generally Accepted Accounting Practice}.
Company law requires the Trustees to prepare Financial Statements for each financial year. Under
company law the Trustees must not approve the Financial Statements unless they are satisfied that they
give a true and fair view of the state of affairs of the charitable company and of the incoming resources
and application of resources, including the Income and expenditure, of the charitable company for that
period.
In preparing these Flnancial Statements, the Trustees are required to:
Select suitable accounting policies and then apply them consistently;
Observe the methods and principles in the Charities SORP;
Make judgements and accounting estimates that are reasonable and prudent,. and
Prepare the Financial Statements on a going concern basis unless it is inappropriate to presume
that the charitable company will continue in operation.
The Trustees are responsible for keeping adequate accounting records that are sufficient to show and
explain the charitable company's transactions and disclose with reasonable accuracy at any time the
financial position of the charitable company and enable them to ensure that the Financial Statements
comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the
charitable company and hence for taking reasonable steps for the prevention and detection of fraud and
other irregularities.
Charity Governance Code
During 2022/23 the Trustees established a working group to review the Charity Governance Code in order
to consider the current governance arrangements in place and whether these could be improved. This
working group made recommendations back to the Board, and an action plan implemented, which we
hope will strengthen governance processes for the future. In particular, the Trustees have acted to put in
place a raft of policies for the Charity along with delegation arrangements to ensure that there is clarity
around the respective roles in the staff team and CEO when taking operational decisions. The Board
continues to seek ways in which the Charity can improve its governance and to ensure that all Board
members can play an active role in decision making.
18

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
{A company limlted by guarantee)
TRUSTEES, REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2024 (continued)
DISCLOSURE OF INFORMATION TO AUDITOR
Each of the persons who are Trustees at the time when this Trustees, Report is approved has confirmed
that:
So far as that Trustee is aware, there is no relevant audit information of which the charitable
Company's Auditor is unaware; and
That Trustee has taken all steps that ought to have been taken as a Trustee in order to be aware
of any information needed by the charitable Compan￿5 Auditor in connection with preparing its
reports and to establish that the charitable Company's Auditor is aware of that information.
AUDITOR
The Auditor, Crowe U.K. LLP, has indicated its willingne55 to continue in office.
This report was approved by the Trustees on 30 January 2025 and signed on their behalf by:
Catherine Jones BA ACG
Chalr
19

INDEPENDENT AUDITOR'S REPORTTO THE MEMBERS OF NORTH WEST CANCER RESEARCH
(INCORPORATING CLAThERBRIDGE CANCER RESEARCH "CCR")
OPINION
We have audited the Financial Statements of North West Cancer Research (Incorporating
Clatterbridge Cancer Research "CCR"} I'the charitable Company,) and its subsidiary {'the group'l for
the year ended 30 September 2024 which comprise the Consolidated Statement of Financial Activities,
the Consolidated Balance Sheet, the Charity Balance Sheet, the Consolidated Cash Flow Statement and
Notes to the Financial Statements, including significant accounting policies. The financial reporting
framework that has been applied in their preparation is applicable law and United Kingdom
Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard
applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting
Practice).
In our opinion the Financial Statements:
give a true and fair view of the state of the Group's and the charitable Company's affairs as at 30
September 2024 and of the Group's income and expenditure, for the year then ended,.
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting
Practice. and
have been prepared in accordance with the requirements of the Companies Act 2006.
BASIS FOR OPINION
We conducted our audit in accordance with International Standards on Auditing (UK) {ISAs IUKII and
applicable law. Our responsibilities under those standards are further described in the Auditor's
responsibilities for the audit of the Financial Statements section of our report. We are independent of
the charitable Group in accordance with the ethical requirements that are relevant to our audit of the
Financial Statement5 in the UK, including the FRC'S Ethical Standard, and we have fulfilled our other
ethical responsibilities in accordance with these requirements. We believe that the audit evidence we
have obtained is sufficient and appropriate to provide a basis for our opinion.
CONCLUSIONS RELATING TO GOING CONCERN
In auditing the Financial Statements, we have concluded that the Trustees, use of the going concern
basis of accounting in the preparation of the Financial Statements is appropriate,
Based on the work we have performed, we have not identified any material uncertainties relating to
events or conditions that, individually or collectively, may cast significant doubt on the charita ble
Company's or the Group's ability to continue as a going concern for a period of at least twelve months
from when the Financial Statements are authorised for issue.
Our responsibilities and the responsibilities of the Trustees with respect to going concern are
described in the relevant sections of this report.
20

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NORTH WEST CANCER RESEARCH
(INCORPORATING CLAThERBRIDGE CANCER RESEARCH "CCR")
OTHER INFORMATION
The Trustees are responsible for the other information contained within the Annual Report. The other
information comprises the information included in the Annual Report, other than the Financial
Statements and our Auditor's Report thereon. Our opinion on the Financial Statements does not cover
the other information and, except to the extent otherwise explicitly stated in our report, we do not
express any form of assurance conclusion thereon.
Our responsibility is to read the other information and, in doing so, consider whether the other
information is materially inconsistent with the Financial Statements or our knowledge obtained in the
audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or
apparent material misstatements, we are required to determine whether this gives rise to a material
Inisstatement in the Financial Statements themselves. If, based on the work we have performed, we
onclude that there is a material misstatement of this other information, we are required to report
that fact.
We have nothing to report in this regard.
OPINIONS ON OTHER MAThERS PRESCRIBED BY THE COMPANIES ACT 2006
In our opinion based on the work undertaken in the course of our audit
the information given in the Trustees, Report, which includes the Directors, Report prepared for
the purposes of company law, for the financial year for which the Financial Statement5 are
prepared is consistent with the Financial Statements. and
the Directors, Report included within the Trustees, Report have been prepared in accordance with
applicable legal requirements.
MAThERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION
In light of the knowledge and understanding of the Group and charitable Company and their
environment obtained in the course of the audit, we have not identified material misstatements in the
Directors, Report included within the Trustees, Report.
We have nothing to report in respect of the following matters in relation to which the Companies Act
2006 requires us to report to you if, in our opinion:
adequate and proper accounting records have not been kept; or
the Financial Statements are not in agreement with the accounting record5 and returns; or
certain disclosures of Trustees, remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit; or
the Trustees were not entitled to prepare the Financial Statements in accordance with the small
companies regime and take advantage of the small companies, exemption5 in preparing the
Trustees, Directors, Report and from the requirement to prepare a strategic report.
21

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NORTH WEST CANCER RESEARCH
(INCORPORATING CLAThERBRIDGE CANCER RESEARCH "CCR")
RESPONSIBILITIES OF TRUSTEES
As explained more fully in the Trustees, Responsibilities Statement set out on page 17, the Trustees
{who are also the Directors of the charitable Company for the purposes of company law) are
responsible for the preparation of the Financial Statements and for being satisfied that they give a
true and fair view, and for such internal control as the Trustees determine is necessary to enable the
preparation of Financial Statements that are free from material misstatement, whether due to fraud
or error.
In preparing the Financial Statements, the Trustees are responsible for assessing the Group's or the
charitable Company's ability to continue as a going concern, disclosing, as applicable, matters related
to going concern and using the going concern basis of accounting unless the trustees either intend to
liquidate the charitable Company or to cease operations, or have no realistic alternative but to do so.
AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS
Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole
are free from material misstatement, whether due to fraud or error, and to 155ue an Auditor's Report
that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee
that an audit conducted in accordance with ISAS {UK} will always detect a material misstatement when
it exlsts. Misstatements can arise from fraud or error and are considered material if, individually or in
the aggregate, they could reasonably be expected to influence the economic decisions of users taken
on the basis of these Financial Statement5.
Details of the extent to which the audit was considered capable of detecting irregularities, including
fraud and non-compliance with laws and regulations are set out below.
A further description of our responsibilitie5 for the audit of the Financial Statements is located on the
Financial Reporting Council's website at: www.frc.or
auditorsres
on5ibilities. This description
forms part of our Auditorfs Report.
EXTENT TO WHICH THE AUDIT WAS CONSIDERED CAPABLE OF DETECTING IRREGULARITIES,
INCLUDING FRAUD
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We
identified and assessed the risks of material misstatement of the Financial Statements from
irregularities, whether due to fraud or error, and discussed these between our audit team members.
We then designed and performed audit procedures responsive to those risks, including obtaining audit
evidence sufficient and appropriate to provide a basis for our opinion.
We obtained an understanding of the legal and regulatory frameworks within which the charitable
Company and Group operates, focusing on those laws and regulations that have a direct effect on the
determination of material amounts and disclosures in the Financial Statements. The laws and
regulations we considered in this context were the Companie5 Act 2006, the Charities Act 2011
together with the Charities SORP IFRS 102). We assessed the required compliance with these laws and
regulations as part of our audit procedures on the related financial statement items.
22

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NORTH WEST CANCER RESEARCH
(INCORPORATING CLAThERBRIDGE CANCER RESEARCH "CCR")
EXTENT TO WHICH THE AUDIT WAS CONSIDERED CAPABLE OF DETECTING IRREGULARITIES,
INCLUDING FRAUD (CONTINUED)
In addition, we considered provisions of other laws and regulations that do not have a direct effect on
the Financial Statements but compliance with which might be fundamental to the charitable
Company's and the Group's ability to operate or to avoid a material penalty. We also considered the
opportunities and incentives that may exist within the charitable Company and the Group for fraud.
The laws and regulation5 we considered in this context for the UK operations were the Charities Act
Regulations.
Auditing standards limit the required audit procedures to identify non-compliance with these laws and
regulations to enquiry of the Trustees and other management and inspection of regulatory and legal
correspondence, if any.
We identified the greatest risk of material impact on the Financial Statements from irregularities,
including fraud, to be within the timing of recognition of voluntary income and the override of
controls by management. Our audit procedures to respond to these risks included enquiries of
management about their own identification and assessment of the risks of irregularities, sample
testing on the posting of journals, reviewing accounting estimates for biases, reviewing regulatory
correspondence with the Charity Commission, sample testing of voluntary income and reading
minutes of meetings of those charged with governance.
Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have
detected some material misstatements in the Financial Statements, even though we have properly
planned and performed our audit in accordance with auditing standards. For example, the further
removed non-compliance with laws and regulations lirregularitiesl is from the events and transactions
reflected in the Fina ncial Statements, the less likely the inherently limited procedures required by
auditing sta ndards would identify it. In addition, as with any audit, there remained a higher risk of
non-detection of irregularities, as these may involve collusion, forgery, intentional omissions,
misrepresentations, or the override of internal controls. We are not responsible for preventing non-
compliance and cannot be expected to detect non-compliance with all laws and regulations.
USE OF OUR REPORT
Thls report is made solely to the charitable Company's members, as a body, in accordance with
Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we
might state to the charitable company's members those matters we are required to state to them in
an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept
or assume responsibility to anyone other than the charitable company and the charitable company's
members as a body, for our audit work, for this report, or for the opinions we have formed.
23

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NORTH WEST CANCER RESEARCH
IINCORPORATING CLA￿ERBRIDGE CANCER RESEARCH "CCR")
Michael Jayson
Senior Statutory Auditor
For and on behalf of
Crowe U.K. LLP
Statutory Auditor
3rd floor
St Georges House
56 Peter Street
Manchester M2 3NQUK
4 April 2025
24

NORTH WEST CANCER RESEARCH {INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
REGISTERED NUMBER: 2165552
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES
(INCORPORATING THE INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 30 SEPTEMBER 2024
Restated
Total
funds
2023
Unrestricted Restricted
funds
Funds
2024
2024
Total
Funds
2024
Note
INCOME FROM:
Donations a nd legacies
Other trading activities
Investment income
1,957,373
110,189
315,942
454,184
2,411,557
110,189
315,942
2,618,720
280,125
TOTAL INCOME
2,383,504
454,184
2,837,688
2,898,845
EXPENDITURE ON:
Raisi ng funds
Investment management
Charltable activltles
921,915
31,310
2,744,420
921,915
31,310
3,223,311
771,211
29,638
2,539,317
478,891
TOTAL EXPENDITURE
3,697,645
478,891
4,176,536
3,340,166
NET
INCOME/IEXPENDITURE)
BEFORE INVESTMENT GAINS
Gains/llos5esl on investments
11,314,141)
124,707) {1,338,848)
1441,321)
1,104,660
1,104,660
231,351
NET
INCOME/(EXPENDITURE)
BEFORE TRANSFERS
Transfers between funds
1209,481)
{24,707) 1234,188
(209,9701
NET MOVEMENT IN FUNDS
{209,481)
(24,707) (234,188)
(209,9701
RECONCILIATION OF FUNDS:
Total funds brought forward
5,176,760
24,707
5,201,467
5,411,437
TOTAL FUNDS CARRIED
FORWARD
4,967,279
4,967,279
5,201,467
The Notes on pages 29 to 52 form part of the Financial Statements.
25

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
REGISTERED NUMBER: 2165552
CONSOLIDATED BALANCE SHEET
AS AT 30 SEPTEMBER 2024
Restated
2023
2024
Note
FIXED ASSETS
Tangible a55ets
Investments
io
li
151.895
9,263,371
963
8,232,986
9,415,266
8,233,949
CURRENT ASSETS
Stocks
Debtors
Debtors.. amounts falling due after
more than one year
Investments- short term
Cash at bank and in hand
12
13
20,691
554,205
21,096
413,398
13
140,327
59,000
14
1.416,027
538,445
2,027,452
640,662
2,669,695
3,161,608
CREDITORS: amounts falling due in
less than one year
15 (4,497,157)
13,946,017)
NET CURRENT ASSETS/{LIABILITIES)
(1,827,462)
1784,409)
TOTAL ASSETS LESS CURRENT
LIABILITIES
7,587,804
7,449,540
CREDITORS: amounts falling due
after more than one year
16
(2,620,525)
{2,248,0731
NET ASSETS
4,967,279
5,201,467
CHARITY FUNDS
Restricted funds
Unrestricted fund5
18
18
24,707
5,176,760
4,967,279
TOTAL FUNDS
4,967,279
5,201,467
The Company's Financial Statements have been prepared in accordance with the provisions applicable
to companies subject to the small companies regime. The Financial Statements were approved and
th
authorised for issue by the Trustees on 30 January 2025, and s
ned on their behalf, by..
Miss C Jones BA ACG,
ir
Mrs J Clague BA FCA, Treasurer
The Notes on pages 29 to 52 form part of these Financial Statements.
26

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
CHARITY BALANCE SHEET
AS AT 30 SEPTEMBER 2024
2024
2023
Note
FIXED ASSETS
Tangible assets
Investments
io
li
7,969
9,094,607
963
8,084,279
9,102,576
8,085,242
CURRENT ASSETS
Stocks
Debtors
Debtors: amounts falling due after
more than one year
Investments- short term
Cash at bank and in hand
12
13
20,691
677,430
21,096
568,348
13
329,419
127,414
14
1,416,027
510,559
2,027,451
542,502
2.954,126
3,286,810
CREDITORS: amounts falling due in
less than one year
15 (4,399,803)
(3,943,557)
NET CURRENT ASSETS/(LIABILITIES)
11,445,677)
{656,7471
TOTAL ASSETS LESS CURRENT
LIABILITIES
7,656,899
7,428,495
CREDITORS: amounts falling due
after more than one year
16
(2,620,525
12,248,073)
NET ASSETS
5,036,374
5,180,422
CHARITY FUNDS
Restricted f unds
Unrestricted funds
18
18
24,707
5,155,715
5,036,374
TOTAL FUNDS
5,036,374
5,180,422
The Company's Financial Statements have been prepared in accordance with the provisions applicable
to companies subject to the small companies regime. The Financial Statements were approved and
authorised for issue by the Trustees on 30 January 2025, and signed on their behalf, by:
Miss C Jones BA ACG,
ir
Mrs J Clague BA FCA, Treasurer
The Notes on pages 29 to 52 form part of these Financial Statements.
27

NORTH WEST CANCER RESEARCH (INCORPORATING CLA￿ERBRIDGE CANCER
RESEARCH "CCR")
{A company limited by guarantee)
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 SEPTEMBER 2024
Note
2024
2023
Cash flows from operating activities:
Net cash used in operating activities
20
(940.549)
210,396
Cash flows from investing activities:
Dividends and interest from investments
Purchase of tangible fixed assets
Proceeds from the sale of investments
Purchase of investments
315,942
(163,312}
3,632,767
1,635,311
(3,032,498) 12,907,033)
280,125
Net cash provided by investing activities
752,899
1991,597)
Change in cash and cash equivalents in the year
Cash and cash equivalents brought forward
1187,650}
1,383,534
1781,2011
2,164,735
Cash and cash equivalents carried forward
21
1,195,884
1,383,534
28

NORTH WEST CANCER RESEARCH (INCORPORATING CLAThERBRIDGE CANCER
RESEARCH "CCR")
IA company limited by Euaranteel
I. ACCOUNTING POLICIES
1.1 Basis of preparation of Financial Statements
The Financial Statements have been prepared in accordance with Accounting and Reporting by
Charities: Statement of Recommended Practice applicable to charities preparing their accounts in
accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 102)
(effective l January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in
the UK and Republic of Ireland {FRS 102) and the Companies Act 2006.
North West Cancer Research (incorporating Clatterbridge Cancer Research "CCR") meets the definition
of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost
or transaction value unless otherwise stated in the relevant accounting policy.
The accompanying Consolidated Financial Statements include the Financial Statement5 of North West
Cancer Research, and its consolidated subsidiaries (together referred to as the Charity). NWCR'S
subsidiaries are listed in note 11. Wherea5, last year, the results of North West Cancer Research Trading
Limited were not consolidated because the company did not trade during the year and had no assets,
thls year they have been, with prior year figures restated where applicable.
No separate SOFA has been presented for the Charity alone as permitted by section 408 of the
Companies Act 2006,
NWCR was created by merger of two charities: Clatterbridge Cancer Research and North West Cancer
Research Fund. The principal object and activityof both charitieswasto promote and carry out research
into cancer. The merger took effect from l November 2012.
1.2 Company status
The Company is a company limited by guarantee. In the event of the Company being wound up, the
liability is respect of the guarantee is limited to £1 per member of the Company.
1.3 Going concern
The Financial Statements have been prepared on a going concern basis, which principally assumes that
the Company will continue to receive an adequate level of income to meet its anticipated requirements.
This was reviewed in light of the Covid-19 pandemic and the impact that this had on the Charity sector,
along with the impact on investments and resenies. During the pandemic the Trustees adopted prudent
plans and reduced commitments to new research funding. However, the positive financial results for
2022/23 meant that the Trustees were able to enter into an increased number of new commitments
and to return to close to earlier levels.
29

NORTH WEST CANCER RESEARCH {INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by Euarantee)
I. ACCOUNTING POLICIES (continued)
On that basis the Trustees consider it appropriate to prepare the Financial Statements on a going
concern basis.
1.4 Consolidated Financial Statements
These Financial Statements consolidate the results of the Charity and its subsidiary undertakings. The
consolidation has been undertaken on a line by line basis.
Although a separate charity (registration no. 3268121, the results for the subsidiary Cancer and Polio
Research Fund have been consolidated into the Group accounts because the parent charity has the
power to govern the financial and operating pollcies of the entity, and benefits from its activities.
The Charity has taken advantage of the exemption available to a qualifying entity in FRS 102 from the
requirement to present a Charity only Cash Flow Statement with the consolidated accounts.
1.5 Income
All income is recognised once the Company has entitlementto the income, it is probable thatthe income
will be received and the amount of income receivable can be measured reliablv.
For legacies, entitlement is taken as the earlier of the date on which either: the Company is aware that
probate has been granted, the estate has been finalised and notification has been made by the
executor{s} to the Trust that a distribution will be made, or when a distribution is received from the
estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be
measured reliably and the Company has been notified of the executorfs intention to make a distribution.
Where legacies have been notified to the Company, or the Company is aware of the granting of probate,
and the criteria for income recognition have not been met, then the legacy is treated as a contingent
asset and disclosed if material.
Donated services or facilities are recognised when material and the Company has control over the item,
any conditions associated with the donated item have been met, the receipt of the economic benefit
from the use of the Company of the item is probable and that economic benefit can be measured
reliably. In accordance with the Charities SORP (FRS 1021, the general volunteer time of the branches /
committees is not recognised- reference should be made to the Trustees, Report for more information
about their contribution.
30

NORTH WEST CANCER RESEARCH (INCORPORATING CLAThERBRIDGE CANCER
RESEARCH "CCR")
IA company limited by guarantee)
I. ACCOUNTING POLICIES (continued)
On receipt, donated professional services and donated facilities are recognised on the basis of the value
of the gift to the Company which is the amount the Company would have been willing to pay to
obtaining services or facilities of equivalent economic benefit on the open market,, a corresponding
amount is then recognised in expenditure in the period of receipt.
Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is
recognised at the time of the donation.
Income tax recoverable in relation to investment income is recognlsed at the time the investment
income 15 receivable.
1.6 Expendlture
Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit
to a third party, it is probable that a transfer of economic benefits will be required in settlement and
the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs
of each actlvity are made up of the total of direct costs and shared costs, including support costs
involved in undertaking each activlty. Direct costs attributable to a single activity are allocated directly
to that activity. Shared costs which contribute to more than one activity and support costs which are
not attributable to a single activity are apportioned between those activities on a basls consistent with
the use of resources. Central staff costs are allocated on the basis of time spent.
Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of
disseminating information in support of the charitable activities. Support costs are those costs incurred
directly in support of expenditure on the objects of the Company and include project management
carried out at headquarters. Governance costs are those incurred in connection with administration of
the Company and compliance with constitutional and statutory requirements.
Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in
trading activitie5 that raise funds.
Charitable activities and Governance costs are costs incurred on the Company's charitable operations,
including support costs and costs relating to the governance of the Company apportioned to charitable
activities.
Grants payable are charged in the year when the offer is made, except in those cases where the offer is
conditional, such grants being recognised as expenditure when the conditions attached are fulfilled.
All resources expended by the parent charity are inclusive of irrecoverable VAT.
31

NORTH WEST CANCER RESEARCH {INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee}
I. ACCOUNTING POLICIES Icontinued)
1.7 Tangible fixed assets and depreciation
For the main charity, all assets costing more than £1,000 are capitalised. For the trading company, shop
refurbishments are capitalised when the shop fit is complete.
Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment.
Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated
residual va lue, over their expected useful lives on the following bases:
Shop buildings and improvements
Head Office office equipment
5 years (or, where shorter, lease length)
2 years (current lease length)
1.8 Investments
Fixed asset investments are a form of financial instrument and are initially recognised at thelr
transaction cost and subsequently measured at their fair value at the balance sheet date, unless fair
value cannot be measured reliably, in which case it is measured at cost less impairment.
Investment gains and losses, whether reali5ed or unrealised, are combined and shown in the heading
'Ga ins / Ilossesl on Investments, in the Statement of Financial Activities.
1.9 Interest receivable
Interest on funds held on deposit is included when receivable and the amount can be measured reliably
by the Company,. this is normally upon notification of the interest paid or payable by the Bank.
1.10 Operatlng leases
Rentals under operating leases are charged to the Statement of Financial Activities on a straight line
basis over the lease term.
1.11 Stocks
Stocks are valued at the lower of cost and net realisable value after making due allowance for obsolete
and slow-moving stocks.
32

NORTH WEST CANCER RESEARCH (INCORPORATING CLA￿ERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
I. ACCOUNTING POLICIES (continued)
1.12 Debtors
Trade and other debtors are recognised at the settlement amount after any trade discount offered.
Prepayments are valued at the amount prepaid net of any trade discounts due.
1.13 Cash at Bank and in hand
Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity
of three months or less from the date of acquisition or opening of the deposit or similar account.
1.14 Liabilities and provislons
Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past
event, it is probable that a transfer of economic benefit will be required in settlement, and the amount
of the settlement can be estimated reliably. Liabilities are recognised at the amount that the Company
anticipates it will pay to settle the debt or the amount it has received as advanced payment for the
goods and services it must provide. Provisions are measure at the best estimate of the amounts
required to settle the obligation.
1.15 Taxatlon
The parent company is a registered charity and has no liability to corporation tax under its charitable
activities, to the extent that surpluses are applied to its charitable purposes.
The subsidiary trading company is subject to corporation tax but, as no profit was made in the year, no
tax is due.
1.16 Financial instruments
The Company only has financial assets and financial liabilities of a kind that qualify as basic fi nancial
instru ments. Basic financial instruments are initially recognised at transaction value and subsequently
measured at their settlement date.
1.17 Pensions
The Company contributes to personal pension plans and the pension charge represents the amounts
payable by the Company to the plans in respect of the period.
33

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
IA company limited by guarantee)
I. ACCOUNTING POLICIES (continued)
1.18 Fund accounting
General funds are unrestricted funds which are available for the use at the discretion of the Trustees in
furtherance of the general objectives of the Company and which have not been designated for other
purposes.
Restricted funds are funds which are to be used in accordance with specific restrictions imposed by
donors or which have been raised by the Company for particular purposes. The costs of raising and
administerlng such funds are charged against the specific fund. The aim and use of each restricted fund
is set out in the Notes to the Financial Statements.
Where the effect of the time value of money is material, the provision is based on the present value of
those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the lia bility,
The unwinding of the discount rate is recognised within interest payable and similar charges.
1.19 Crltlcal accounting judgements and estimates
The key source of estimation uncertainty in the Financial Statements are residuary legacies. Legacies
are recognised when the income criteria detailed in note 1.5 are considered to be met. In some
circumstances, the legacy has not been received at the year end and is included within debtors, Due to
the nature of residuary legacies receivable, there is judgement applied to the valuation of the legacy.
Where the effect of the time value of money is material to liabilities and provisions, the liability or
provision is based on the present value of those amounts, discounted at the pre-tax discount rate that
reflects the risks specific to the liability. The unwinding of the discount rate is recognised within interest
payable and similar charges. In the 2023124 Financial Statements there were no instances where the
time value of money was material and therefore no discounting has taken place.
The estimates and underlying assumptions are reviewed regularly. Revisions to accounting estimates
are recognised in the period in which the estimate is revised where the revision affects only that period,
or in the period of the revision and future periods where the revision affects both current and future
periods.
34

NORTH WEST CANCER RESEARCH (INCORPORATING CLArrERBRIDGE CANCER
RESEARCH "CCR")
IA company limited by guarantee)
2. INCOME FROM DONATIONS AND LEGACIES
Group- Current Year
Unrestricted
Funds
2024
Restricted
funds
2024
Total
Funds
2024
Legacles
Donations
Donations-in-kind
539,016
1,385,158
33,199
105,000
644,016
349,184 1,734,342
33,199
Total donations and legacies
1,957,373
454,184 2,411,557
Group- Prior Year
Unrestrlcted Restricted
Funds
funds
2023
2023
Total
Funds
2023
Legacies
Donation5
Donations-ln-kind
945,445
1,389,256
97,988
945,445
186,031 1,575,287
97,988
Total donations and legacies
2,432,689
186,031 2,618,720
Charlty- Current Year
Unrestrlcted Restricted
Funds
funds
2024
2024
Total
Funds
2024
Legacies
Donations
Donations-in-kind
539,016
1,391,220
33.199
105,000
644,016
349,184 1.740,404
33,199
Total donations and legacies
1,963,435
454,184 2,417,619
35

NORTH WEST CANCER RESEARCH (INCORPORATING CLArrERBRIDGE CANCER
RESEARCH "CCR, )
(A company limited by guarantee)
Charity- Prior Yeor
Unrestricted Restrlcted
Funds
funds
2023
2023
Total
Funds
2023
Legacies
Donations
Donations-in-kind
944,859
1.392,104
97,988
944,859
186,031 1,578,135
97,988
Total donations and legacies
2,434,951
186,031 2,620,982
3. OTHER TRADING ACTIVITIES
Group
Unrestrlcted and Unrestricted and
Total Funds
Total Funds
2024
2023
Chority
Unrestrlcted
Unrestricted
and Total Funds and Total Funds
2024
2023
Income from
trading subsldiary
110,189
41,761
110,189
41,761
4. INVESTMENT INCOME
Group
Unrestricted and Unrestricted and
Total Funds
Total Funds
2024
2023
Charity
Unrestricted
Unrestricted
and Total Funds and Total Funds
2024
2023
Listed investments
Short term gilts
Bank interest
Loan interest
268,144
42,406
5,392
257,038
8,049
15,038
264,596
42,406
5,392
8,187
254,079
8,049
15,039
315,942
280,125
320,581
277,167
36

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
5. ANALYSIS OF GRANTS
Group and Charity
Unrestricted Unrestricted
and total
and total
Funds
funds
2024
2023
Grants to
Institutions
2024
Grants approved in the year
The total above of £2,571,73812023: £1,955,494) includes £55,441 {2023: £45,256) by way of non-
salary related support costs, for example, expenditure on the NWCR Symposium in July 2024, impact
reporting and overheads.
As disclosed in Note 7, Analysis of Resources Expended by Expenditure Type, the Research Grant
Expenditure charged in the Statement of Financial Activities includes associated staff costs of
£124,97612023.' £98.1381, as well as a share of central charity costs of £29,80212023: £33,598}.
RECONCILIATION OF GRANTS PAYABLE
2024
2023
Accrued at l October 2023
Grants made in the year- Liverpool
Grants made in the year- Lancaster
Grants made in the year- Bangor
Grants made in the year- Royal Preston Hospital
Grants made in the year- Manchester
Grants made in the year- UCLAN
Grants made in the year~ Edgehill
Grants made in the year- Liverpool John Moores
Grants made in the year- Betsi Cadwaladr Univ. Health Board
Grants made in the year- Clatterbridge Cancer Centre
Grants made in the year- Manchester Metropolitan Univ.
Grants made in the year- University of Edinburgh
Grants made in the year- Oracle Head and Neck
Grants cancelled or recovered
Grants paid and other movements
5,757,791
786,435
592,182
7,000
5,699,691
1,285,108
392,448
21,900
147,694
49,894
122,864
196,065
20,000
240,335
146,785
274,822
336,303
40,000
(95,571)
11,721,104)
1109,670)
(1,852,138)
Accrued at 30 September 2024
6,552,984
5,757,791
Payable as follows:
Grants payable <lyr- institutional
Grants payable >lyr- institutional
3,932,459
2,620,525
3,509,718
2,248,073
Total grants payable
6,552,984
5,757,791
37

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
6. GOVERNANCE COSTS
Group
Unrestricted
and Total
Funds
2024
Unrestricted
and Total
Funds
2023
Governance- Auditorfs remuneration
Governance- legal and professional fees
Governance - share of support costs
Governance- recruitment fees
Governance- wages and salaries
Governance- depreciation- tangible fixed assets
17,174
1,740
31,938
3,800
93,713
647
16,356
1,944
32,541
3,800
95,529
263
149,012
150,433
The figure for auditor's remuneration includes £2,58312023: £2,460} in respect of the audit of the
subsidiary Cancer and Polio Research Fund. This is the only element which is not a cost to the chaidrty
on its own.
7. ANALYSIS OF RESOURCES EXPENDED BY EXPENDITURE TYPE
Group
Staff costs Depreclation
2024
2024
Other costs
2024
Total
2024
Expenditure on:
Fundraising
Trading activities
Investment management
388,742
84,439
2,683
7,432
372,869
65,750
31,310
764,294
157,621
31,310
Cost of generatlng funds
473,181
10,115
469,929
953,225
Expenditure on:
Research grants
Education and outreach
Governance
124,976
109,449
93,713
862
755
647
2,600,678 2,726,516
237,579
347,783
54,652
149,012
Charltable activities
328,138
2,264
2,892,909 3.223,311
801.319
12,379
3,362,838 4,176,536
38

NORTH WEST CANCER RESEARCH (INCORPORATING CLAThERBRIDGE CANCER
RESEARCH "CCR")
IA company limited by guarantee}
7. ANALYSIS OF RESOURCES EXPENDED BY EXPENDITURE TYPE (continued)
Group
Staff costs Depreciation
Restated
2023
Other costs
Total
Restated Restated
2023
2023
2023
Expenditure on:
Fundraising
Trading activities
Investment management
304,475
31,129
837
425,347
9,423
29,638
730,659
40,552
29,638
Cost of generating funds
335,604
837
464,408
800,849
Expenditure on..
Research grants
Education & outreach
Governance
98,138
102,013
95,529
271
280
263
1,988,821 2,087,230
199,360
301,653
54,641
150,433
Charitable actlvltles
295,680
814
2,242,823 2,539,317
631,284
1,6SI
2,707,231 3,340,166
8. NET EXPENDITURE
2024
2023
This is Stated after charging:
Depreciation of tangible fixed assets:
Owned by the Charity
Owned by its subsidiaries
4,948
7,432
1,651
Auditor's remuneration:
Fees payable to the charit¢s auditor for the audit of the
Charity's financial statements
14,591
13,896
Audit of the Charity's subsidiaries
7,792
2,460
During the year, no Trustees received any remuneration12023: £01.
During the year, no Trustees received any benefits in kind12023: £0).
During the year, 2 Trustees received reimbursement of travel and accommodation expenses of £392
{2023: £2171.
39

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH'CCR")
{A company limited by Euarantee
9. STAFF COSTS
Staff costs were as follows".
Group
2024
Charlty
2024
2023
Restated
2023
Restated
Wages and salaries
Social security costs
Other pension costs
698,652
67,046
35,621
550,417
52,258
28,609
625,092
59,642
32,146
523,537
49,281
27,337
801,319
631,284
716,880
600,155
There are no redundancy payments included in wages and salaries12023: £nil).
The average number of persons (headcount) employed by the Group during the year was as follows:
Group
Charity
2024
2023
Restated
No.
2024
2023
Restated
No.
No.
No.
Cha ritable activities
Fundraising and Marketlng
Administration
Retail trading subsidiary
10
io
18
15
16
14
The Trustees have delegated significant authority and responsibility in the day-to-day running of the
Charity to its key management personnel. The Charity considers its key management personnel to
comprise the Chief Executive Officer, the Director of Brand and Income (formerly Head of Marketing
and Fundraising), the Head of Health, Research and Impact, and the Head of Finance & Administration.
The total employee benefits, includin
employer National Insurance and employer pension
contributions, of the key management personnel were £263,604 (2023: £221,300).
The number of employees whose total employee benefits, excludin
employer national insurance and
pension costs, for the reporting period fell within the following ranges, was:
40

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
IA company limited by Euarantee)
9. STAFF COSTS (continued)
Group and Charity
2024
2023
No.
£60,000- £69,999
£80,000- £89,999
10. TANGIBLE FIXED ASSETS
Group
Charity
Leasehold
Office
Propertles Equlpment
Office
Equipment
Total
Total
Cost
At l October 2023
Additions
Disposals
8,256
11,953
18,256)
8,256
163,311
(8,256)
8,256
11,953
(8,256)
8,256
11,953
18,256)
151,358
At 30 September 2024
151,358
11,953
163,311
11,953
11,953
Depreclatlon
At l October 2023
Charge for the year
On disposals
7,293
4,947
(8256)
7,293
12,379
(8,256)
7,293
4,947
18,256)
7,293
4,947
(8,256)
7432
At 30 September 2024
7,432
3,984
11,416
3,984
3,984
Net book value
At 30 September 2024
143,926
7,969
151,895
7,969
7,969
At 30 September 2023
963
963
963
963
41

NORTH WEST CANCER RESEARCH (INCORPORATING CLArrERBRIDGE CANCER
RESEARCH "CCR")
IA company limited by guarantee)
11. FIXED ASSET INVESTMENTS
Listed
securitles
(Market value)
Group
Cash
Total
At l October 2023
Additions
Disposals
Movement in cash for the year
Realised and unrealised gains
on investments
7,998,164
1,213,212
(1,049,170)
234,822
8,232,986
1,213,212
{1,049,170)
(189,969)
{189,969)
1,056,312
1,056,312
At 30 September 2024
9,218,518
44,853
9,263,371
Listed
securitles
(Market value)
Group
Undertakings
Charlty
Cash
Total
At l October 2023
Additions
Disposals
Movement in cash for the year
Realised and unrealised gains
on investments
7,849,456
1,209,663
(1,049,170)
234,822
8,084,279
1,209,663
11,049,170)
{189,969)
1189,969)
1,039,804
1,039,804
At 30 September 2024
9,049,754
44,853
9,094,607
Group subsidiary undertakings
The following were subsidiary undertakings of the Company:
Narne
Holding
North West Cancer Research Trading Limited
(company registration no. 082806501
loo%
Cancer and Polio Research Fund Limited
Icompany registration no. 723861: charity no. 3268121
loo%
42

NORTH WEST CANCER RESEARCH (INCORPORATING CLA￿ERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
11. FIXED ASSET INVESTMENTS (continued)
The aggregate of the share capital and reserves as at 30 September 2024 and of the profit or10ss for
the year ended related to the Charity's subsidiary undertakings were as follows:
Aggregate of
share capital
and reserves
Profit / (loss)
Name
NW Cancer Research Trading Ltd.
Cancer and Polio Research Fund Limited
Total
(135,885)
66,791
169,094)
(95,334}
5,195
190,139)
Group and Charlty materlal restrlctlons
The Company has barred investment in tobacco businesses. In addition the Trustees have agreed that
the charity should not make new investments in holdings which promote low-cost alcohol or
irresponsible drinking, draw the majority of their profits from alcohol or draw their prof its exclusively
from sugar. Investments are primarily held to provide a balance between capital growth and income in
order to meet the Company's future commitments.
12. STOCKS
Group
2024
Charity
2024
2023
2023
Goods for resale
20,691
21,096
20,691
21,096
Included above is £6,81012023: £8,732) of new stock donated to the charity and not used by year end.
This has been valued at half of its RRP, which is considered to be a reasonable approximation of its value.
13, DEBTORS
Group
Restated
2023
Charity
Restated
2023
2024
2024
Trade and other debtors
VAT recoverable
Prepayments
Accrued legacy income
Other accrued income
Amounts owed by group and subsidiaries
9,327
21,810
43,906
126,429
493,060
20,107
674
20,156
47,437
384,024
9,326
20,107
23,617
126,429
640,729
206,748
20,156
47,437
608,062
694,532
472,398 1,006,849
695, 762
43

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH'CCR, )
(A company limited by guarantee}
13. DEBTORS ICONTINUED)
Included above within 'Other accrued income, for the Charity is £504,98112023: £177,102) of income
from other charities where North West Cancer Research has jointly funded research projects with
them. Of this amount, £265,184 {2023: £9,730) is shown as restricted income in the Statement of
Financial Activities.
Included within 'Other accrued income, in the prior year results was £41,226 owed by North West
Cancer Research Trading Ltd. to the Charity at the balance sheet date, comprising set-up costs for the
retail operation. The prior year figure has been restated to eliminate this figure on consolidation,
13,2 Analysis of debtors recoverable in more than l year (included in debtors above):
Group
2024
Charity
2024
2023
2023
Trade and other debtors
Taxation recoverable
Prepayments
Accrued legacy income
Other accrued income
Amounts owed by group and subsidiaries
140,327
59,000
164,419
165,000
127,414
140,327
59,000
329,419
127,414
Note 13.2 shows that element of the 'Other accrued income, figure of £504,981 (2023: £177,102)
referred to above that is judged to be recoverable in more than I year because of length of jointly
funded research projects.
The figure for the charity also includes income due for research projects from its subsidiary Cancer and
Polio Research Fund where, because of the length of those projects, that debtor is judged to be
recoverable in more than one year.
Under 'Amounts owed by group and subsidiaries,, the sum of £165,00012023: £0) represents the
value of the loan made by the charity to the trading company for securing, and fitting out, its shops,

NORTH WEST CANCER RESEARCH (INCORPORATING CLA￿ERBRIDGE CANCER
RESEARCH "CCR")
IA company limited by guarantee)
14. INVESTMENTS- SHORT TERM
Llsted
securities
(Market value)
Group and Charity
Cash
Total
At l October 2023
Additions
Disposals
Movement in cash for the year
Realised and unrealised gains
on investments
1,519,402
1,819,296
(2,583,597)
508,049
2,027,451
1,819,296
(2,583,597)
104,529
104,529
48,348
43,348
At 30 September 2024
803,449
612,578
1,416,027
15. CREDITORS: Amounts falllng due wlthln one year
Group
2024
Charity
2024
2023
2023
Trade creditors
Sundry creditors
Amounts owed to NWCRT, the subsidiary
company
Other taxation and social security
Accruals and deferred income
Grants accrued - institutional (see note 4)
171,585
146,064
91,364
146,064
2,047
24,492
20,318
21,479
20,318
368,621
196,453
352,455
193,993
3,932,459 3,583,182 3,932,459 3,583,182
4,497.157 3,946,017 4,399,803 3,943,558
16. CREDITORS: Amounts falling due after more than one year
Group
2024
Charity
2024
2023
2023
G rants accrued - institutional (see note 41
2,620,525 2,248,073 2,620,525 2,248,073
45

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
{A company limited by guarantee)
17. FINANCIAL INSTRUMENTS
Group
Charity
Restated
2023
2024
2024
2023
Financlal assets measured at fair value
I nvestments
9,263,371 8,232,986 9,094,607 8,084,280
Financial assets measured at amortised cost
Debtors excluding prepayments
650,626
452,242
983,233
675,606
Financial liabllltles measured at amortised
cost
Creditors
7,117,681 6,194,090 7,020,307 6,191,632
18, STATEMENT OF FUNDS
GROUP STATEMENT OF FUNDS- CURRENT YEAR
Balance at
l October
2023
Balance at
Gains1 30 September
(Losses)
2024
Transfers
In/Out
Income Expenditure
Unrestricted
funds
Other
General
funds
5,176,760
2,383,504 13,697,645)
1,104,660
4,967,279
Restricted
funds
Other
Restricted
Funds
24,707
454,184
(478,891)
Total funds
5,201,467
2,837,688 (4,176,536)
1,104,660
4,967,279
Restricted income in the current year comprises: £265,184 {2023.. £9,730) due from other charities
where North West Cancer Research has jointly funded research projects with them; grants of £84,000
(2023.. £175,513) made to the Charity by various Trusts and Foundations, towards education and
outreach projects and campaigns. and income of £105,00012023: £0) from one legacy left to fund
research at a specific University.
46

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
18. STATEMENT OF FUNDS continued
Restricted expenditure of £478,89112023: £95,536) comprises the value of education and outreach
work undertaken during the year on specific projects for which grants were received, as well as the
cost of grant- and legacy-funded research projects approved in the year. No income has been received
to support ongoing research projects approved in prior years, so there are no transfers between
funds.
GROUP STATEMENT OF FUNDS- PRIOR YEAR
Balance at
l October
Balance at
30 September
Restated
2023
Restated
Income Expenditure
Transfers
In/Out
Gains/
{Lossesl
2022
Unrestrlcted
funds
Other
General
funds
5,411,437
2,712,814 {3,244,630)
65,788
231,351
5,176,760
Restricted
funds
Other
restricted
funds
186,031
(95,536) (65,7881
24,707
Total funds
5,411,437
2,898,845
{3,340,166)
231,351
5,201,467
Restricted income in the prior year included £9,730 (2022: £99,576) due from other charities where
North West Cancer Research had jointly funded research projects with them, as well as grants of
£175,51312022: nil) made to the Charity by various Trusts and Foundations, towards both research
and education and outreach projects. No legacies with specific conditions attached {2022: £657,994)
were received during the year.
Restricted expenditure in the prior year of £95,536 (2022: £104,576) comprised the value of education
and outreach work undertaken during the year on specific projects for which grants were received, as
well as the cost of grant-funded research projects approved in the year. Where income had been
received to support ongoing research projects approved in prior years, an equivalent figure to the
value of that income was treated as a transfer between restricted and unrestricted funds, with
conditions of the income fulfilled.
47

NORTH WEST CANCER RESEARCH (INCORPORATING CLAThERBRIDGE CANCER
RESEARCH "CCR")
IA company limited by guarantee)
18. STATEMENT OF FUNDS continued
CHARITY STATEMENT OF FUNDS- CURRENT YEAR
Balance at
l October
2023
Balance at
Gains1 30 September
(Losses}
2024
Transfers
In/Out
Income Expenditure
Unrestrlcted
funds
Other
funds
General
5,155,715 2,325,777 (3,533,271)
1,088,152
5,036,374
Restricted funds
Other restricted
funds
24,707
454,184
(478,891)
Total funds
5,180,422 2,779,961 (4,012,162)
1,088,152
5,036,374
CHARITY STATEMENT OF FUNDS- PRIOR YEAR
Balance at
l October
2022
Balance at
Gains1 30 September
{Losses}
2023
Transfers
In/Out
Income Expenditure
Unrestrlcted
funds
Other General
funds
5,358,903 2,712,118 13,201,094)
65,788
220,000
5,155,715
Restricted
funds
Other
restricted
funds
186,031
{95,536}
{65,788)
24,707
Total funds
5,358,903 2,898,149 (3,296,630)
220,000
5,180,422
48

NORTH WEST CANCER RESEARCH {INCORPORATING CLA￿ERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
19. ANALYSIS OF NET ASSETS BETWEEN FUNDS
ANALYSIS OF NET ASSETS BETWEEN FUNDS- CURRENT YEAR
Group
Unrestricted
and total
funds
2024
Restrlcted
funds
2024
Total
funds
2024
Tangible fixed assets
Fixed asset investments
Current assets
Creditors due within one year
Creditors due in more than one year
151,896
9,263,371
2,669,695
4,497,157
2,620,525
151,896
9,263,371
2,669,695
4,497,157
2,620,525
4,967,279
4,967,279
ANALYSIS OF NET ASSETS BETWEEN FUNDS- PRIOR YEAR
Group
Unrestricted
and total
funds
Restated
2023
Restricted
funds
Restated
2023
Total
funds
Restated
2023
Tangible fixed assets
Fixed asset investments
Current assets
Creditors due within one year
Creditors due in more than one year
963
8,232,986
3,131,901
13,941,017)
12,248,073)
963
8,232,986
29,707
3,161,608
15,0001 13,946,017}
{2,248,0731
5,176,760
24,707
5,201,467
49

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
20. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING
ACTIVITIES
Restated
2023
2024
Net income/ (expenditure) for the year (as per Statement of Financial
Activities)
(234,188)
1209,9701
Adjustment for:
Depreciation charges
12,379
1,651
IGains}/Losses on investments
Dividends, interest and rents from investments
Assets acquired
(Increase}/ decrease in stocks
(Increasel/ decrease in debtors
Increase/ldecrease) in creditors
(1,104,660)
{315,942)
1231,3511
1280,1251
405
(222,134)
923,591
13,9031
805,427
128,667
Net cash used in operating activities
(940,549)
210,396
21. ANALYSIS OF CASH AND CASH EQUIVALENTS
Group
2024
2023
Cash in hand
Investment cash accounts
538,445
657,439
640,662
742,872
1,195,884
1,383,534
22. RECONCILIATION OF NET DEBT
Group
At l October
2023
Cashflow
At30
September
2024
Cash in hand and at bank
1,383,534
(187,650)
1,195,884
1,383,534
1187,650)
1,195,884
50

NORTH WEST CANCER RESEARCH (INCORPORATING CLAThERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
23. PENSION COMMITMENTS
The Charity contributes to personal pension plans for eligible employees, who are automatically
enrolled. The assets of those plans are held separately from those of the Charity, in independently
administered funds. Contributions totalling £5,560 (2023: £4,634), covering pension commitments for
both North West Cancer Research and North West Cancer Research Trading Ltd., were payable to the
plans at the balance sheet date and are included in creditors.
24. OPERATING LEASE COMMITMENTS
At 30 September 2024 the total of the Group's future minimum lease payments under non-cancellable
operating leases was:
Group
2024
2023
Within one year
Between two and five years
In over f ive yea rs
50,732
191,945
1,272
4,770
242,677
6,042
Charity
2024
2023
Within one year
Between two and five years
I n over f ive years
1,332
3,678
1,272
4,770
5,010
6,042
51

NORTH WEST CANCER RESEARCH (INCORPORATING CLAThERBRIDGE CANCER
RESEARCH "CCR")
(A company limited by guarantee)
25. RELATED PARTY TRANSACTIONS
There are two related party transactions of note:
At the period end £1 was owed to North West Cancer Research Trading Ltd. (formerly
Clatterbridge Cancer Research Ltd.), the subsidiary company. Two of the Charity's Trustees,
Hilary Atherton and Sandeep Anantharaman serve as Directors of this Company along with a
number of others who are not connected to the Charity.
Three of the Charity's Trustees, Miss C M Jones, Dr. M Carter and Mr. P Moonan, serve as
Directors of Cancer and Polio Research Fund Ltd. and, in matters concerning that Charity, act
only in the interest of the Cancer and Polio Research Fund
26. RESTATEMENT IN RELATION TO 2023 PREVIOUSLY PRESENTED FIGURES
In the prior year accounts, the results of North West Cancer Research Trading Limited were not
consolidated into the Group on the grounds of materiality. This wa5 because the company had not
commenced trading and had no assets, only a liability owed to its parent company (included in these
accounts as a debtor). This year the results have been consolidated, and the prior year figures restated
where applicable. The impact of this is shown below.
Prior to
Restatement
2023
Adjustment
2023
Restated
2023
Expenditure - fundraising
Debtors
730,659
512,950
40,552
(40,5521
771,211
472,398
Funds
5,242,019
(40,5521
5,201,467
52